BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30509492)

  • 1. SR 57227A is a partial agonist/partial antagonist of 5-HT
    Nakamura Y; Kondo M; Koyama Y; Shimada S
    Biochem Biophys Res Commun; 2019 Jan; 508(2):590-596. PubMed ID: 30509492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.
    Thompson AJ; Lummis SC
    Br J Pharmacol; 2013 Sep; 170(2):391-402. PubMed ID: 23822584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo.
    Bachy A; Héaulme M; Giudice A; Michaud JC; Lefevre IA; Souilhac J; Manara L; Emerit MB; Gozlan H; Hamon M
    Eur J Pharmacol; 1993 Jun; 237(2-3):299-309. PubMed ID: 7689975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of NMDA-receptor mediated response in the rat medial prefrontal cortical pyramidal cells by the 5-HT3 receptor agonist SR 57227A and 5-HT: intracellular studies.
    Liang X; Arvanov VL; Wang RY
    Synapse; 1998 Jul; 29(3):257-68. PubMed ID: 9635896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct modification of the 5-HT
    Nakamura Y; Ishida Y; Kondo M; Shimada S
    Eur J Pharmacol; 2018 Feb; 821():21-28. PubMed ID: 29277715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subunit-dependent inhibition and potentiation of 5-HT3 receptor by the anticancer drug, topotecan.
    Nakamura Y; Ishida Y; Yamada T; Kondo M; Shimada S
    J Neurochem; 2013 Apr; 125(1):7-15. PubMed ID: 23305320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Yokukansan contains compounds that antagonize the 5-HT
    Nakamura Y; Ishida Y; Kondo M; Shimada S
    Phytomedicine; 2018 Apr; 43():120-125. PubMed ID: 29747744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes.
    Oz M; Zhang L; Morales M
    Synapse; 2002 Dec; 46(3):150-6. PubMed ID: 12325042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
    Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
    Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bupropion Inhibits Serotonin Type 3AB Heteromeric Channels at Clinically Relevant Concentrations.
    Stuebler AG; Jansen M
    Mol Pharmacol; 2020 Mar; 97(3):171-179. PubMed ID: 31871303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtle Differences among 5-HT
    Price KL; Hirayama Y; Lummis SCR
    ACS Chem Neurosci; 2017 May; 8(5):1085-1091. PubMed ID: 28367632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT
    Dale E; Grunnet M; Pehrson AL; Frederiksen K; Larsen PH; Nielsen J; Stensbøl TB; Ebert B; Yin H; Lu D; Liu H; Jensen TN; Yang CR; Sanchez C
    Brain Res; 2018 Jun; 1689():1-11. PubMed ID: 29274875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.
    Yang KH; Galadari S; Isaev D; Petroianu G; Shippenberg TS; Oz M
    J Pharmacol Exp Ther; 2010 May; 333(2):547-54. PubMed ID: 20160007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superagonist, Full Agonist, Partial Agonist, and Antagonist Actions of Arylguanidines at 5-Hydroxytryptamine-3 (5-HT
    Alix K; Khatri S; Mosier PD; Casterlow S; Yan D; Nyce HL; White MM; Schulte MK; Dukat M
    ACS Chem Neurosci; 2016 Nov; 7(11):1565-1574. PubMed ID: 27533595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a 5-HT
    Price KL; Lummis SCR
    ACS Chem Neurosci; 2018 Jun; 9(6):1409-1415. PubMed ID: 29508995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo modulation of the firing activity of putative slow- and fast-spiking interneurons in the medial prefrontal cortex by 5-HT3 receptors in 6-hydroxydopamine-induced Parkinsonian rats.
    Gui ZH; Zhang QJ; Liu J; Ali U; Li LB; Wang Y; Wang T; Chen L; Hou C; Fan LL
    Neuroscience; 2010 Sep; 169(3):1315-25. PubMed ID: 20576497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
    Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
    Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ginsenoside Rg2 on the 5-HT3A receptor-mediated ion current in Xenopus oocytes.
    Choi S; Lee JH; Oh S; Rhim H; Lee SM; Nah SY
    Mol Cells; 2003 Feb; 15(1):108-13. PubMed ID: 12661769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents.
    Poncelet M; Perio A; Simiand J; Gout G; Soubrie P; Le Fur G
    J Neural Transm Gen Sect; 1995; 102(2):83-90. PubMed ID: 8748673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drug irinotecan inhibits homomeric 5-HT3A and heteromeric 5-HT3AB receptor responses.
    Nakamura Y; Ishida Y; Yamada T; Shimada S
    Biochem Biophys Res Commun; 2011 Nov; 415(2):416-20. PubMed ID: 22044840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.